Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.
|Published (Last):||22 March 2008|
|PDF File Size:||2.81 Mb|
|ePub File Size:||15.6 Mb|
|Price:||Free* [*Free Regsitration Required]|
Access to the full text of this article requires a subscription.
RMLG – ACCES A L’ARTICLE :COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE (LMC).
If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: Chronic myeloid leukaemia in South African blacks. Contact Help Who are we? The persistence of TKI-refractory leukemic stem cells could explain this result. Imatinib chroniqye therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: Access to the PDF text.
Indian J Hematol Blood Transfus. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed. Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction. Chronic myeloid leukaemia in central Africans. S Af Med J. N Engl J Med.
You can move this window by clicking on the headline. As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data.
An experience from eastern India.
Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be lehcemie in the future. Access to the text HTML. Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.
Molecular biology of bcr-abl1-positive CML.
Clinical and pronognostic features of Nigerians with chronic myeloid leukemia. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. East Afr Med J. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. If you are a subscriber, please sign in ‘My Account’ at the top right of the screen. New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods.
The Glivec international patient assistance programme: Clinical trials have validated TKI discontinuation strategies in patients with sustained deep molecular response. Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall and disease-free survival of patients.
Journal page Archives Contents list. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used cchronique stored, be corrected, clarified, updated or deleted. Outline Masquer le plan.
There was a problem providing the content you requested
Personal information regarding our website’s visitors, including their identity, is confidential. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties. International recommendations facilitate the management of CML and treatment adjustments.
A chgonique study of leukemia epidemiology in Northern Tunisia. Les inhibiteurs des kinases.
Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. Top of the page – Article Outline.
Chronic myeloid leukemia advances in biology and new approaches to treatment.